Newsroom
Frontier Medicines Appoints Veteran Drug Development Leader David R. Epstein to Board of Directors
April 13, 2026
Recent Press Releases
Presentations
There are currently no upcoming events scheduled
Events
There are currently no upcoming events scheduled
Publications
A practical method for determining the rate of covalent modification of fragments and leads
Jeon J, Kholodar SA, Tran BH, Mallinger KE, Erlanson DA, Everley RA.Nat Commun. 2025 Dec 18;16(1):11234. doi: 10.1038/s41467-025-66924-0. PMID: 41413335
Fragment-to-Lead Medicinal Chemistry Publications in 2024: A Tenth Annual Perspective
Twigg DG, Arai K, Arkin MR, Erlanson DA, de Esch IJP, Farkaš B, Fesik SW, Jahnke W, Johnson CN, Schroeder M.J Med Chem. 2025 Dec 11;68(23):24830-24847. doi: 10.1021/acs.jmedchem.5c02894. Epub 2025 Nov 25. PMID: 41290421
Structural basis for DCAF2 as a novel E3 ligase for PROTAC-mediated targeted protein degradation
McMahon EJ, Cioffi AG, Visperas PR, Lin Y, Shaghafi M, Daczkowski CM, Hermann JC, Everley RA, Neve RM, Erlanson DA, Webster KR, Narayan V, Wang W.Structure. 2025 Dec 4;33(12):2020-2028.e7. doi: 10.1016/j.str.2025.09.006. Epub 2025 Oct 3. PMID: 41045927
Where and how to house big data on small fragments
Erlanson DA, Burley SK, Fearon D, Fraser JS, Kreitler D, Nonato MC, Sakai N, Wollenhaupt J, Weiss MS.Nat Commun. 2025 May 5;16(1):4179. doi: 10.1038/s41467-025-59233-z. PMID: 40325009
Fragment-to-Lead Medicinal Chemistry Publications in 2023
Holvey RS, Erlanson DA, de Esch IJP, Farkaš B, Jahnke W, Nishiyama T, Woodhead AJ.J Med Chem. 2025 Jan 23;68(2):986-1001. doi: 10.1021/acs.jmedchem.4c02593. Epub 2025 Jan 6. PMID: 39761118
Fragment-to-Lead Medicinal Chemistry Publications in 2022
Woodhead AJ, Erlanson DA, de Esch IJP, Holvey RS, Jahnke W, Pathuri P.J Med Chem. 2024 Feb 22;67(4):2287-2304. doi: 10.1021/acs.jmedchem.3c02070. Epub 2024 Jan 30. PMID: 38289623
Fragment-to-Lead Medicinal Chemistry Publications in 2021
Walsh L, Erlanson DA, de Esch IJP, Jahnke W, Woodhead A, Wren E.J Med Chem. 2023 Jan 26;66(2):1137-1156. doi: 10.1021/acs.jmedchem.2c01827. Epub 2023 Jan 9. PMID: 36622056
Fragment-to-Lead Medicinal Chemistry Publications in 2020
de Esch IJP, Erlanson DA, Jahnke W, Johnson CN, Walsh L.J Med Chem. 2022 Jan 13;65(1):84-99. doi: 10.1021/acs.jmedchem.1c01803. Epub 2021 Dec 20. PMID: 34928151
Targeting mutant KRAS
Erlanson DA, Webster KR.Curr Opin Chem Biol. 2021 Jun;62:101-108. doi: 10.1016/j.cbpa.2021.02.010. Epub 2021 Apr 7. PMID: 33838397
FMC-376 a dual inhibitor of states of KRASG12C is broadly active in PDX models of resistance
Yan Wang, Richard M. Neve, Jocelyn Staunton, Kevin R. Webster
The clinical dual KRASG12C inhibitor FMC-376 has demonstrated potential as both a monotherapy and in combination for the treatment of patients with KRASG12C mutation positive NSCLC
Yan Wang, Allison Roberts, Philamer Calses, Richard M. Neve, Jocelyn Staunton, Kevin R. Webster
Combining Chemoproteomics with Machine Learning Identifies Functional Covalent Fragments for Hard-to-Drug Cancer Drivers
2023 American Association for Cancer Research Annual Meeting (Abstract 1142)
Select Media Coverage
Fierce Biotech: AACR: Verastem, Quanta and Frontier demonstrate KRAS inhibitors’ potential in preclinical data
April 11, 2024
Fierce Biotech: Frontier CEO weathers ‘one of the hardest financings’ of his career to close $80M series C
February 22, 2024
San Francisco Business Times: Peninsula biotech raises $80M as it doses 1st person in 1st clinical trial
February 22, 2024